Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 20 12:16PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-29.20 Insider Own3.04% Shs Outstand0.53M Perf Week7.53%
Market Cap0.88M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float0.52M Perf Month8.24%
Income-16.24M PEG- EPS next Q- Inst Own4.23% Short Float8.53% Perf Quarter-49.97%
Sales0.00M P/S- EPS this Y- Inst Trans- Short Ratio0.30 Perf Half Y-48.40%
Book/sh-1.12 P/B- EPS next Y- ROA-176.90% Short Interest0.04M Perf Year-92.35%
Cash/sh1.28 P/C1.29 EPS next 5Y- ROE-525.19% 52W Range1.31 - 22.80 Perf YTD-59.18%
Dividend Est.- P/FCF- EPS past 5Y- ROI- 52W High-92.74% Beta-
Dividend TTM- Quick Ratio0.45 Sales past 5Y0.00% Gross Margin- 52W Low26.41% ATR (14)0.22
Dividend Ex-Date- Current Ratio0.45 EPS Y/Y TTM89.71% Oper. Margin0.00% RSI (14)47.39 Volatility16.33% 14.83%
Employees4 Debt/Eq- Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price1520.00
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q-31.86% Payout- Rel Volume0.18 Prev Close1.64
Sales Surprise- EPS Surprise84.62% Sales Q/Q- Earnings- Avg Volume148.07K Price1.66
SMA20-0.23% SMA50-9.19% SMA200-67.13% Trades Volume11,935 Change0.98%
Date Action Analyst Rating Change Price Target Change
Sep-15-21Initiated Maxim Group Buy $11
May-16-24 11:53AM
Mar-14-24 08:30AM
Feb-26-24 07:00AM
Dec-04-23 09:00AM
Nov-28-23 09:00AM
04:29PM Loading…
Aug-14-23 04:29PM
Aug-10-23 08:46AM
Aug-07-23 09:00AM
Aug-03-23 08:00AM
Jul-31-23 08:00AM
Apr-10-23 04:30PM
Apr-05-23 01:00PM
Feb-27-23 08:30AM
Feb-23-23 07:30AM
Feb-22-23 04:30PM
08:45AM Loading…
Jan-25-23 08:45AM
Jan-17-23 08:00AM
Jan-05-23 08:30AM
Jan-04-23 08:30AM
Dec-29-22 08:30AM
Dec-23-22 08:00AM
Dec-20-22 02:11PM
Dec-16-22 09:00AM
Nov-30-22 05:00PM
Nov-21-22 08:30AM
Nov-15-22 12:37PM
Sep-26-22 08:30AM
Aug-22-22 08:30AM
Jul-27-22 08:30AM
08:00AM Loading…
Jul-21-22 08:00AM
Jul-18-22 08:30AM
Jun-22-22 04:05PM
Jun-14-22 04:15PM
May-31-22 08:30AM
May-02-22 08:00AM
Apr-29-22 06:32PM
Feb-17-22 08:30AM
Jan-31-22 08:00AM
Dec-28-21 11:00AM
Dec-15-21 08:15AM
Dec-12-21 06:06AM
Dec-10-21 05:15PM
Dec-06-21 08:15AM
Dec-01-21 02:45PM
Nov-22-21 08:30AM
Nov-18-21 08:15AM
Nov-03-21 12:06PM
Oct-26-21 08:30AM
Sep-30-21 08:30AM
Sep-20-21 08:00AM
Aug-30-21 08:30AM
Aug-24-21 08:30AM
Aug-19-21 09:00AM
Aug-02-21 08:00AM
Jul-29-21 08:00AM
Jul-28-21 08:15AM
Jul-20-21 08:00AM
Jul-12-21 09:51AM
Jul-07-21 08:00AM
Jun-28-21 08:15AM
Jun-10-21 09:12AM
Jun-01-21 08:00AM
May-28-21 08:00AM
May-21-21 04:45PM
Apr-20-21 08:00AM
Apr-19-21 05:00PM
Apr-14-21 08:15AM
Mar-26-21 08:30AM
Mar-25-21 08:30AM
Mar-24-21 08:30AM
Mar-08-21 01:30PM
Feb-24-21 04:00PM
Feb-19-21 09:00AM
Feb-17-21 12:00AM
Jan-11-21 08:00AM
Jan-05-21 02:50PM
Dec-03-20 11:08AM
Nov-24-20 10:00AM
Nov-23-20 08:30AM
Nov-17-20 08:00AM
Nov-10-20 11:46AM
180 Life Sciences Corp. operates as a clinical-stage biotechnology company, which engages in the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. The company was founded by Marc Feldmann, Lawrence J. Steinman, and Jonathan B. Rothbard on September 7, 2016 and is headquartered in Palo Alto, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Woody James N.Chief Executive OfficerDec 15 '23Buy0.1925,0004,70066,888Dec 18 04:15 PM
Feldmann MarcDirectorDec 15 '23Sale0.1925,0004,700115,497Dec 18 04:15 PM